The European Commission (EC) has approved AbbVie’s Rinvoq (upadacitinib) for the treatment of active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
These new data also confirm sustained improvement in signs and symptoms in almost 80 percent of patients, with a favourable and consistent safety profile